These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12187237)

  • 21. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
    Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
    Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.
    Ferro A; Bae HJ; Yenokyan G; Le Y; McNutt T; Mian O; Gergis C; Haviland C; DeWeese TL; Song DY
    Brachytherapy; 2018; 17(2):313-318. PubMed ID: 29174937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regarding Blasko et al. palladium-103 brachytherapy for prostate carcinoma. IJROBP 2000;46:839-850.
    Vikram B
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1267. PubMed ID: 11228645
    [No Abstract]   [Full Text] [Related]  

  • 24. Radioactive seeds for prostate cancer.
    Zietman A
    Health News; 1998 Oct; 4(13):4-5. PubMed ID: 9803172
    [No Abstract]   [Full Text] [Related]  

  • 25. [(125)I versus (103)Pd brachytherapy for low risk prostate cancer: a systematic review].
    Zhang LL; Ma L; Tian JH; Ren YY; Yang KH
    Ai Zheng; 2009 Aug; 28(8):872-8. PubMed ID: 19664336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate implant dosimetric outcomes and migration patterns between bio-absorbable coated and uncoated brachytherapy seeds.
    Sarkar A; Donavanik V; Zhang I; Chen H; Koprowski C; Hanlon A; Mourtada F; Strasser J; Raben A
    Brachytherapy; 2013; 12(4):356-61. PubMed ID: 23477885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate brachytherapy seed migration to the right ventricle found at autopsy following acute cardiac dysrhythmia.
    Davis BJ; Pfeifer EA; Wilson TM; King BF; Eshleman JS; Pisansky TM
    J Urol; 2000 Nov; 164(5):1661. PubMed ID: 11025737
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiac and hepatic seed implant embolization after prostate brachytherapy.
    Nguyen BD
    Urology; 2006 Sep; 68(3):673.e17-9. PubMed ID: 16979711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of seed migration after transperineal interstitial prostate brachytherapy with I-125 free seeds.
    Sugawara A; Nakashima J; Shigematsu N; Kunieda E; Kubo A
    Brachytherapy; 2009; 8(1):52-6. PubMed ID: 19154979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation pneumonitis caused by a migrated brachytherapy seed lodged in the lung.
    Miura N; Kusuhara Y; Numata K; Shirato A; Hashine K; Sumiyoshi Y; Kataoka M; Takechi S
    Jpn J Clin Oncol; 2008 Sep; 38(9):623-5. PubMed ID: 18676993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calibration, calculation, and prescription issues in permanent prostate brachytherapy with (103)Pd.
    Bice WS; Prestidge BR; Sarosdy MF
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):289-91. PubMed ID: 11163528
    [No Abstract]   [Full Text] [Related]  

  • 32. Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy.
    Stone NN; Stock RG
    Urology; 2005 Jul; 66(1):119-23. PubMed ID: 15992909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate implant therapy: iodine-125 versus palladium-103.
    Peschel RE
    Cancer J; 2005; 11(5):383-4. PubMed ID: 16259868
    [No Abstract]   [Full Text] [Related]  

  • 34. The retrospective analysis of the relationship between prescribed dose and risk factor for seed migration in iodine-125 prostate brachytherapy.
    Hirose K; Aoki M; Sato M; Akimoto H; Hashimoto Y; Imai A; Kamimura N; Kawaguchi H; Hatayama Y; Fujioka I; Tanaka M; Ohyama C; Takai Y
    Jpn J Radiol; 2016 Nov; 34(11):718-723. PubMed ID: 27631882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
    Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Migration of prostate brachytherapy seeds to the vertebral venous plexus.
    Nakano M; Uno H; Gotoh T; Kubota Y; Ishihara S; Deguchi T; Hayashi S; Matsuo M; Tanaka O; Hoshi H
    Brachytherapy; 2006; 5(2):127-30. PubMed ID: 16644468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Seed migration to the vertebral venous plexus after prostate brachytherapy].
    Wagner W; Willich N; Radmard A; Christ A; Fleig PW; Krukemeyer MG
    Urologe A; 2010 Nov; 49(11):1390-2. PubMed ID: 20835698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritricuspid annular prostate pellet.
    O'Sullivan B; Tanner R; Kelly P; Fahy G
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33574044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seed implant retention score predicts the risk of prolonged urinary retention after prostate brachytherapy.
    Lee HK; Adams MT; Shi Q; Basillote J; Lamonica J; Miranda L; Motta J
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1445-9. PubMed ID: 19553032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of brachytherapy in the definitive management of prostate cancer.
    Crook J
    Cancer Radiother; 2011 Jun; 15(3):230-7. PubMed ID: 21514199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.